Maurice Perol
Overview
Explore the profile of Maurice Perol including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
147
Citations
5446
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
12.
Perol M, Solomon B, Goto K, Park K, Nadal E, Bria E, et al.
J Clin Oncol
. 2024 Jun;
42(21):2500-2505.
PMID: 38828957
JCO .Although the CNS activity of selpercatinib in patients with fusion-positive non-small cell lung cancer (NSCLC) has been previously described, the ability of potent RET inhibition to prevent new CNS...
13.
Friedlaender A, Perol M, Banna G, Parikh K, Addeo A
Biomark Res
. 2024 Feb;
12(1):24.
PMID: 38347643
Lung cancer ranks among the most common cancers world-wide and is the first cancer-related cause of death. The classification of lung cancer has evolved tremendously over the past two decades....
14.
Dessemon J, Perol O, Chauvel C, Noelle H, Coudon T, Grassot L, et al.
Front Public Health
. 2024 Feb;
11:1306455.
PMID: 38328545
Introduction: Residential exposure is estimated to be responsible for nearly 10% of lung cancers in 2015 in France, making it the second leading cause, after tobacco. The Auvergne-Rhône-Alpes region, in...
15.
Zhou C, Solomon B, Perol M
N Engl J Med
. 2024 Jan;
390(4):381-382.
PMID: 38265654
No abstract available.
16.
Reguart N, Perol M, Cortinovis D, Puntis S, Ohrling K, Archangelidi O, et al.
Future Oncol
. 2023 Nov;
20(17):1151-1164.
PMID: 38031886
To investigate changes in treatment patterns in extensive-stage small-cell lung cancer (ES-SCLC) in France, Germany, Italy, Spain and the UK (EU5) between 2018 and 2021. Cross-sectional data from an oncology...
17.
Zhou C, Solomon B, Loong H, Park K, Perol M, Arriola E, et al.
N Engl J Med
. 2023 Oct;
389(20):1839-1850.
PMID: 37870973
Background: Selpercatinib, a highly selective potent and brain-penetrant RET inhibitor, was shown to have efficacy in patients with advanced fusion-positive non-small-cell lung cancer (NSCLC) in a nonrandomized phase 1-2 study....
18.
Decroisette C, Greillier L, Curcio H, Perol M, Ricordel C, Auliac J, et al.
J Immunother
. 2023 Oct;
PMID: 37807621
Outside clinical trials, few data are available on the effect of long-term first-line pembrolizumab in patients with advanced non-small-cell lung cancers with ≥50% of tumor cells expressing programmed cell death...
19.
Goto K, Goto Y, Kubo T, Ninomiya K, Kim S, Planchard D, et al.
J Clin Oncol
. 2023 Sep;
41(31):4852-4863.
PMID: 37694347
Purpose: Trastuzumab deruxtecan (T-DXd) 5.4 and 6.4 mg/kg showed robust antitumor activity in multiple cancer indications; however, T-DXd 5.4 mg/kg has not been evaluated in patients with previously treated human...
20.
Bouhamama A, Leporq B, Faraz K, Foy J, Boussageon M, Perol M, et al.
Front Radiol
. 2023 Jul;
3:1168448.
PMID: 37492391
Introduction: In this study, we aim to build radiomics and multiomics models based on transcriptomics and radiomics to predict the response from patients treated with the PD-L1 inhibitor. Materials And...